The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Official Title: Phase-I/II Trial to Assess the Safety and Efficacy of Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (FLAMSAClax
Study ID: NCT05807932
Brief Summary: This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und Klinische Immunologie, Düsseldorf, NRW, Germany
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, , Germany
Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, , Germany
Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, , Germany
Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III, München, , Germany
Name: Guido Kobbe, Prof. Dr.
Affiliation: Coordinating Investigator
Role: PRINCIPAL_INVESTIGATOR